Ocera Therapeutics (OCRX) Announces Late-Breaker Presentation of OCR-002 Phase 2a Data in ALF; Says All Doses 'Well Tolerated'
Tweet Send to a Friend
Ocera Therapeutics, Inc. (Nasdaq: OCRX), announced that clinical data from STOP-ALF, a Phase 2a clinical trial to evaluate the Safety ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
